Biostatistics and Epidemiology Consulting

https://github.com/philsf-biostat/analise\_dados\_LT\_2021-v01

# Survival analysis of events attributed to PJI in patients that undergone TJA surgeries

REPORT: analise\_dados\_LT\_2021-v01

From: Felipe Figueiredo To: Lucio Toledo

Date: 2021-04-11

#### **TABLE OF CONTENTS**

<b>TABL</b>	E OF CONTENTS	. 1
1	ABBREVIATIONS	. 2
2	INTRODUCTION	. 3
2.1	Objectives	. 3
2.2	Data reception and cleaning	. 3
3	METHODS	. 3
3.1	Variables	. 3
3.1.1	Outcome and time definition	. 3
3.1.2	Covariates	. 4
3.2	Statistical analyses	. 4
3.2.1	Statistical packages	. 4
4	RESULTS	. 4
4.1	Study population and follow up	. 4

## https://github.com/philsf-biostat/analise\_dados\_LT\_2021-v01

4.2	Mortality	4
4.3	2-year survival rates	8
5	EXCEPTIONS AND OBSERVATIONS	9
6	CONCLUSIONS	9
7	REFERENCES	9
8	APPENDIX	9
8.1	Exploratory data analysis	9
8.2	Alternative results table1	7
8.3	Analytical data-set1	7

## **Document version**

Version	Alterations
01	Initial version

#### **ABBREVIATIONS**

- PJI:
- SD: standard deviation
- SIRS: systemic inflammatory response
- TJA:

Biostatistics and Epidemiology Consulting

#### https://github.com/philsf-biostat/analise\_dados\_LT\_2021-v01

#### 2 INTRODUCTION

#### 2.1 Objectives

Perform a Kaplan-Meier survival analysis on the deaths caused by PJI after a TJA surgical procedure. Additionally, explore possible risk factor for PJI mortality in bi-variate analyses.

#### 2.2 Data reception and cleaning

#### **Analytical data-set**

- 1. ID
- 2. Age; continuous
- 3. Sex; binary
- 4. time (date PJI diagnosis date last follow up)
- 5. event (death due to PJI)
- 6. death (all causes)
- 7. Joint; binary
- 8. SIRS; binary
- 9. Multi-germ infection; binary
- 10. Complication; binary
- 11. Surgery type; categorical
- 12. Surgery success; binary

Obs: Complication Type was considered for analysis, but could not be safely converted to a categorical variable. It was dropped.

#### 3 METHODS

#### 3.1 Variables

#### 3.1.1 Outcome and time definition

The event of interest for this analysis is death caused by the PJI. For the main analysis patients that died from other causes were censored. The time to event was defined as the number of years between the diagnosis of PJI and the last follow up noted.

There were multiple outcomes to consider regarding the mortality in PJI patients. These causes were categorized as being caused by PJI (event of interest), other causes of death and survival (censored). This multi-state outcome was used to assess the competing risks of death under the PJI risk. The follow up time of all participants was considered in the person-year at risk.

Felipe Figueiredo	<b>Biostatistics Consulting</b>	Year	Page
prof.felipefigueiredo@gmail.com	https://github.com/philsf-biostat	2021	3/17

Biostatistics and Epidemiology Consulting

#### https://github.com/philsf-biostat/analise\_dados\_LT\_2021-v01

#### 3.1.2 Covariates

- Sex; binaryJoint; binary
- Complication; binary
- SIRS; binary
- Multi-germ infection; binarySurgery success; binary
- Surgery type; categorical

#### 3.2 Statistical analyses

Demographic characteristics were described with mean (SD) or proportions, where appropriate. Kaplan-Meier curves were computed for the at-risk study population for the event of interest. For all covariates considered the 2-year survival rates were computed for the event of interest. The all-cause mortality was assessed using the competing risks overall figure. Bi-variate analyses were performed using the log-rank test for all covariates considered. All statistical analyses considered the significance level of 5%.

#### 3.2.1 Statistical packages

This analysis was performed using statistical software R version 4.0.5. Packages used for survival analyses were survival version 3.2.10 and survminer version 0.4.9.

#### 4 RESULTS

#### 4.1 Study population and follow up

Of the 54 participants were included, 21 (39%) were male and 33 (61%) were female. Average (SD) age was 64.3 (11.6) years, ranging from 32 to 88 years. Time under observation ranged from 4 days to 16.35 years, where all 54 participants contributed with a total of 239 person-years of follow up.

#### 4.2 Mortality

44 of the 54 patients survived until the last follow up observation. Of the deaths recorded, 5 from other causes and 5 could be attributed to PJI (Fig 1). All deaths attributed to PJI occurred before the deaths unrelated. Figure 2 shows the Kaplan-Meier estimate of the mortality rate attributed to PJI. Times of death ranged from 4 days to 2.13 years. The survival rate at the end of study follow up was 89.7% so the median time of survival could not be estimated. The 1-year survival rate was estimated as 96% (91% - 100%) and the 2-year survival rate was estimated as 92% (85% - 100%).

Felipe Figueiredo	<b>Biostatistics Consulting</b>	Year	Page
prof.felipefigueiredo@gmail.com	https://github.com/philsf-biostat	2021	4/17

Times of deaths unrelated to PJI ranged from 2.37 years to 13.17 years (Fig 1). It is noticeable that, while the analysis does not give proof that there is a significant difference between times of death between all cause this sample seem to indicate that most patients die from PJI within 2 years of the diagnosis (Fig 2).	is s,

https://github.com/philsf-biostat/analise\_dados\_LT\_2021-v01

## Competing risks for causes of death after TJA




Figure 1 Mortality due to all causes.

Felipe Figueiredo	Biostatistics Consulting	Year	Page
prof.felipefigueiredo@gmail.com	https://github.com/philsf-biostat	2021	6/17

Biostatistics and Epidemiology Consulting




Figure 2 Mortality confirmed to be caused by PJI.

Felipe Figueiredo	<b>Biostatistics Consulting</b>	Year	Page
prof.felipefigueiredo@gmail.com	https://github.com/philsf-biostat	2021	7/17

Biostatistics and Epidemiology Consulting

https://github.com/philsf-biostat/analise\_dados\_LT\_2021-v01

#### 4.3 2-year survival rates


Table 1 shows the 2-year survival rates across all covariates considered. In this sample surgical complications decreased the survival (log-rank p=0.038), and most events were related to the procedure of Spacer, where the median time of survival was 3.14 weeks (log-rank p=0.002).

**Table 1** Survival rates for 2-year.

2-year survival	р
92% (85%, 100%)	
	0.275
93% (85%, 100%)	
90% (79%, 100%)	
	0.703
92% (83%, 100%)	
92% (82%, 100%)	
	0.038
100% (100%, 100%)	
82% (68%, 100%)	
	0.056
97% (92%, 100%)	
77% (57%, 100%)	
	0.938
92% (84%, 100%)	
92% (77%, 100%)	
	0.060
84% (67%, 100%)	
100% (100%, 100%)	
	0.002
— (—, —)	
100% (100%, 100%)	
100% (100%, 100%)	
67% (30%, 100%)	
50% (19%, 100%)	
97% (93%, 100%)	
	92% (85%, 100%)  93% (85%, 100%)  90% (79%, 100%)  92% (83%, 100%)  92% (82%, 100%)  100% (100%, 100%)  82% (68%, 100%)  97% (92%, 100%)  77% (57%, 100%)  92% (84%, 100%)  92% (77%, 100%)  84% (67%, 100%)  100% (100%, 100%)  100% (100%, 100%)  100% (100%, 100%)  67% (30%, 100%)  50% (19%, 100%)

Although a significant difference in the status of surgery success was not detected it could be possible that there is a true association between these predictos. This variable had 18 missing values in the sample that were dropped from the analysis. Oh the other hand the effect of a surgical complication is strong enough to be detected even in the presence of 13 missing values in the sample.

- 5 **EXCEPTIONS AND OBSERVATIONS**
- **CONCLUSIONS** 6
- 7 **REFERENCES**
- 8 **APPENDIX**
- 8.1 Exploratory data analysis






Figure 3 Mortality by Sex.

Felipe Figueiredo	Biostatistics Consulting	Year	Page
prof.felipefigueiredo@gmail.com	https://github.com/philsf-biostat	2021	10/17

## https://github.com/philsf-biostat/analise\_dados\_LT\_2021-v01

## Survival by operated Joint






Figure 4 Mortality by joint.

Felipe Figueiredo	<b>Biostatistics Consulting</b>	Year	Page
prof.felipefigueiredo@gmail.com	https://github.com/philsf-biostat	2021	11/17

Biostatistics and Epidemiology Consulting

## https://github.com/philsf-biostat/analise\_dados\_LT\_2021-v01

## Survival given Complications





Figure 5 Mortality under presence of surgical complication.

Felipe Figueiredo	Biostatistics Consulting	Year	Page
prof.felipefigueiredo@gmail.com	https://github.com/philsf-biostat	2021	12/17

Biostatistics and Epidemiology Consulting

## https://github.com/philsf-biostat/analise\_dados\_LT\_2021-v01

## Survival given multi-germ infection







Figure 6 Mortality by Multi-germ.

Felipe Figueiredo	<b>Biostatistics Consulting</b>	Year	Page
prof.felipefigueiredo@gmail.com	https://github.com/philsf-biostat	2021	13/17

## https://github.com/philsf-biostat/analise\_dados\_LT\_2021-v01

## Survival by Confirmed SIRS






Figure 7 Mortality by SIRS.

Felipe Figueiredo	<b>Biostatistics Consulting</b>	Year	Page
prof.felipefigueiredo@gmail.com	https://github.com/philsf-biostat	2021	14/17

## https://github.com/philsf-biostat/analise\_dados\_LT\_2021-v01

## Survival by surgery success






Figure 8 mortality by status of the TJA.

Felipe Figueiredo	Biostatistics Consulting	Year	Page
prof.felipefigueiredo@gmail.com	https://github.com/philsf-biostat	2021	15/17

Biostatistics and Epidemiology Consulting

## https://github.com/philsf-biostat/analise\_dados\_LT\_2021-v01

## Survival by surgery type




Figure 9 Mortality by surgery outcome.

Felipe Figueiredo	Biostatistics Consulting	Year	Page
prof.felipefigueiredo@gmail.com	https://github.com/philsf-biostat	2021	16/17

Biostatistics and Epidemiology Consulting

https://github.com/philsf-biostat/analise\_dados\_LT\_2021-v01

#### 8.2 Alternative results table

Table 2 Optional version of Table 1, adding 1-year survival rates.

Characteristic	1-year survival	2-year survival	р
Overall	96% (91%, 100%)	92% (85%, 100%)	
Sex			0.275
F	100% (100%, 100%)	93% (85%, 100%)	
M	90% (79%, 100%)	90% (79%, 100%)	
Joint			0.703
Hip	96% (89%, 100%)	92% (83%, 100%)	
Knee	96% (89%, 100%)	92% (82%, 100%)	
Complication			0.038
N	100% (100%, 100%)	100% (100%, 100%)	
Υ	92% (81%, 100%)	82% (68%, 100%)	
SIRS			0.056
N	100% (100%, 100%)	97% (92%, 100%)	
Υ	85% (67%, 100%)	77% (57%, 100%)	
Multigerm			0.938
N	98% (93%, 100%)	92% (84%, 100%)	
Υ	92% (77%, 100%)	92% (77%, 100%)	
surg.success			0.060
Failure	93% (80%, 100%)	84% (67%, 100%)	
Success	100% (100%, 100%)	100% (100%, 100%)	
surg.type			0.002
Amputation	100% (100%, 100%)	— (—, —)	
Arthrodesis	100% (100%, 100%)	100% (100%, 100%)	
Exarticulation	100% (100%, 100%)	100% (100%, 100%)	
Girdlestone	100% (100%, 100%)	67% (30%, 100%)	
Spacer	50% (19%, 100%)	50% (19%, 100%)	
TJA	100% (100%, 100%)	97% (93%, 100%)	

#### 8.3 **Analytical data-set**

Due to confidentiality the data-set used in this analysis cannot be shared online in the public version of this report.